Envisagenics partners with Boehringer on AI RNA-splicing cancer targets

Envisagenics published a multi-year research collaboration and option agreement with Boehringer Ingelheim to validate tumor-specific RNA splicing targets via its AI SpliceCore platform for hard-to-treat solid cancers, saying it is eligible for more than US$1 billion in potential payments plus royalties.

HEALTH desk — big pharma is paying AI-native RNA splicing discovery for solid-tumor targets that gene-centric methods miss. RNA splicing is the cell’s step of cutting and rejoining a gene’s message so one gene can make more than one protein.

RNA splicing, in one plain sentence: it is the cell’s step of cutting and rejoining a gene’s RNA message so one gene can make more than one protein. Envisagenics says that step is often thrown off in human cancers, and that the extra protein versions can be specific to the tumor. The company says those versions stay out of reach for conventional, gene-centric discovery — a search that looks at the gene as a whole and misses the extra cut-and-join versions.

The platform is SpliceCore, which the company writes as SpliceCore®. Envisagenics calls it AI-powered. It says the platform combines artificial intelligence, large-scale transcriptomics, and experimental validation. Transcriptomics means reading which RNA messages a tissue is actually making. Experimental validation means a lab check, not only a computer score. The company says SpliceCore screens more than 14 million distinct splicing events, and that it uses them to predict disease specificity, how common a target is among patients, and whether it looks suitable as a drug target. A splicing event is one of those cut-and-join versions. More than 14 million is Envisagenics’ count.

Modalities the release names for possible development: antibody-drug conjugates (ADCs), T-cell engagers (TcEs), and multispecific antibodies. An ADC is an antibody that carries a drug to a marked cell. A T-cell engager is a protein that pulls a T cell, an immune cell, onto a cancer cell. A multispecific antibody is an antibody built to grab more than one target. The collaboration builds on targets Envisagenics says it already found with SpliceCore, and it will validate them further. After the research program, Boehringer Ingelheim has the option to exclusively license selected targets for further development and commercialization. An option is a right to take a license later. It is not a license already signed, and it is not a drug on the market.

Economics, still the company: Envisagenics is eligible to receive more than US$1 billion in potential payments. That pot includes an upfront payment, research funding, option fees, and development, regulatory, and commercial milestones, plus royalties on future product sales. A milestone is an extra payment when a program hits a goal. A royalty is a share of later sales. The upfront dollar amount is not printed. BioSpace’s same-day wrap by Tristan Manalac also reports the more-than-$1-billion figure and calls the upfront unspecified. More than $1 billion is what the company says it could receive if goals are hit. It is not cash already received, and it is not a valuation.

Quote on the company page: Maria Luisa Pineda, Ph.D., chief executive and co-founder of Envisagenics, said the company is proud to partner with Boehringer Ingelheim, and that the collaboration validates Envisagenics’ view that alternative RNA splicing is one of the richest untapped sources of novel disease-specific targets. She said combining SpliceCore with Boehringer’s oncology expertise can speed highly differentiated new medicines for patients. A quote is not a clinical result.

Quote on the same page: Mark Petronczki, global head of oncology research at Boehringer Ingelheim, said growing innovation with partners is central to how Boehringer builds its oncology pipeline, that alternative RNA splicing opens a largely unexplored target space, and that Envisagenics has built a distinctive way to investigate it. He said the hope is to find highly tumor-selective targets for patients still waiting for better options.

BioSpace’s independent wrap adds lines from an email by Maria Pineda that are not on the press release this desk read. She told BioSpace the partners will work closely on target validation studies, that Boehringer will take the lead and full responsibility for modality selection, development, and commercialization of the resulting therapy, and that Boehringer is focused on aggressive solid tumors with significant unmet need and limited treatment options.

Plain English for the rest of the card: RNA splicing = the cell’s step of cutting and rejoining a gene’s message so one gene can make more than one protein. gene-centric = a search that looks at the gene as a whole and can miss those extra versions. solid tumor = a cancer mass in tissue, not a blood cancer. first-in-class = a medicine that works in a new way. SpliceCore = Envisagenics’ AI platform for finding splicing targets. transcriptomics = a readout of which RNA messages a tissue is making. ADC = an antibody that carries a drug to a marked cell. T-cell engager = a protein that pulls an immune cell onto a cancer cell. multispecific antibody = an antibody built to grab more than one target. option = a right to license a target later, not a license already signed. milestone = an extra payment when a program hits a goal. royalty = a share of later sales. more than US$1 billion = potential payments if those goals are hit. The upfront amount was not printed.